Viral Response at Week 2 as a Predicitive Factor for Rvr in Chronic Hepatitis C Genotype 1 Infection Treated With Peginterferon Alfa-2A (PEG) and Ribavirin (RBV)

被引：0
|
作者：
Mauss, Stefan
Lutz, Thomas
Boeker, Klaus H.
Link, Ralph
Moog, Gero
Stoehr, Albrecht D.
Baumgarten, Axel
Heyne, Renate
Eisenbach, Christoph
Teuber, Gerlinde
Weber, Bernd
Schott, Eckart
Hillenbrand, Heribert
Alshuth, Ulrich
Hueppe, Dietrich
Buggisch, Peter
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S958 / S958
页数：1
相关论文
共 50 条
  • [31] Peginterferon alfa-2a plus Low Dose Ribavirin versus Peginterferon alfa-2a Monotherapy for Dialysis Patients with Hepatitis C Virus Genotype 1 Infection: A Randomized Trial
    Liu, Chen-Hua
    Liang, Cheng-Chao
    Su, Tung-Hung
    Hung, Peir-Haur
    Tsai, Hung-Bin
    Liu, Chun-Jen
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    HEPATOLOGY, 2012, 56 : 993A - 993A
  • [32] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Hepatitis C
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18): : 1808 - 1809
  • [33] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [34] Sustained viral response (SVR) with Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who were non responders (NR) to Peginterferon alfa-2b and ribavirin
    Gitlin, N
    Muther, KD
    HEPATOLOGY, 2004, 40 (04) : 343A - 343A
  • [35] Sustained virological response of Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection genotype IV
    Shiha, G.
    Abass, B.
    El-Shenawy, H.
    Zalata, K.
    LIVER INTERNATIONAL, 2006, 26 : 81 - 81
  • [36] Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions
    Hueppe, Dietrich
    Zehnter, Elmar
    Mauss, Stefan
    Kaiser, Stephan
    Schober, Andreas
    Schuchmann, Marcus
    Boeker, Klaus
    Moog, Gero
    Schiffelholz, Willibold
    Pape, Stefan
    Heyne, Renate
    Ackermann, Frank
    Schmidt, Wolfgang
    John, Christine
    Lohmeyer, Juergen
    Hey, Karl-Heinz
    Alshuth, Ulrich
    GASTROENTEROLOGY, 2009, 136 (05) : A839 - A840
  • [37] Response to Pegylated Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4
    El Makhzangy, Hesham
    Esmat, Gamal
    Said, Mohamed
    ElRaziky, Maissa
    Shouman, Soheir
    Refai, Rasha
    Rekacewicz, Claire
    Gad, Rita Raafat
    Vignier, Nicolas
    Abdel-Hamid, Mohamed
    Zalata, Khaled
    Bedossa, Pierre
    Pol, Stanislas
    Fontanet, Arnaud
    Mohamed, Mostafa K.
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (09) : 1576 - 1583
  • [38] Dose Reduction of Peginterferon Alfa-2a (PEG) in Combination With Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patients: Impact on Virological Response Under Real Life Conditions
    Boeker, Klaus
    Mauss, Stefan
    Hueppe, Dietrich
    Schuchmann, Marcus
    Schiffelholz, Willibold
    Raumgarten, Axel
    Eisenhach, Christoph
    Rossle, Martin
    Buggisch, Peter
    Lohmeyer, Juergen
    Witthoeft, Thomas
    Moeller, Bernd
    Loehr, Matthias
    Schott, Eckart
    Alshuth, Ulrich
    Zehnter, Elmar
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [39] Safety and adherence to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with chronic hepatitis C (CHC) HCV genotype 1
    Howell, CD
    Jeffers, LS
    Hu, S
    Lopez-Talavera, JC
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A723
  • [40] DOSE REDUCTION OF PEGINTERFERON ALFA-2A (PEG) IN COMBINATION WITH RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS: IMPACT ON VIROLOGICAL RESPONSE UNDER REAL LIFE CONDITIONS
    Boeker, K.
    Mauss, S.
    Hueppe, D.
    Schuchmann, M.
    Schiffelholz, W.
    Baumgarten, A.
    Eisenbach, C.
    Roessle, M.
    Buggisch, P.
    Lohmeyer, J.
    Witthoeft, T.
    Moeller, B.
    Loehr, H.
    Schott, E.
    Alshuth, U.
    Zehnter, E.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S162 - S162
12345